CureVac and GSK enter pandemic preparedness contract with German government

German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK

– A five-year contract enables the production of up to 80 million doses of vaccine in the short term in the event of a public health emergency, contributing to better preparedness for a pandemic

TÜBINGEN, GERMANY and BOSTON, MA /ACCESSWIRE / April 11, 2022 /CureVac GmbH NV (NASDAQ: CVAC), a global biopharmaceutical company developing a new class of transformative messenger ribonucleic acid (“mRNA”) drugs, and GSK today announced that they have entered into a contract with the German Federal Government to the supply of mRNA vaccines as part of a wider tender for pandemic preparedness in Germany. After a setup period of up to two years, the contract grants the German federal government access to CureVac manufacturing capacity until 2029, enabling rapid availability of 80 million doses of the vaccine based on mRNA during the remainder of the current pandemic or in future infectious disease outbreaks. . By reserving this manufacturing capacity, the tender aims to mitigate the risks associated with potential supply bottlenecks in a pandemic situation. Under the contract, the federal government will pay CureVac and GSK an annual standby fee after the installation period is successfully completed, which requires the companies to maintain their manufacturing capacity at a constant level of readiness. By ensuring the availability of manufacturing capacity in Germany, the arrangement will contribute significantly to strengthening pandemic preparedness.

“Over the past two years, our social and economic lives as well as global health systems and medical supply infrastructures have been severely tested by the COVID-19 pandemic,” said Dr Franz- Werner Haas, Chairman and CEO of CureVac. “This underscored the importance of having access to innovative technology platforms, such as mRNA technology, and corresponding strong manufacturing capabilities to rapidly develop and deliver life-saving vaccines – particularly as a protective measure. in case of future infectious disease emergencies. unpredictable and variable course of the COVID-19 pandemic, we are fully committed to protecting public health now and in the future. »

“We welcome this announcement from the German federal government, which aims to strengthen the country’s preparedness against future pandemics,” said Roger Connor, president of Vaccines and Global Health, GSK. “Our mRNA development program in collaboration with CureVac could play a key role in pandemic preparedness thanks to the adaptability of mRNA technology and its potential for rapid response, in combination with our significant expertise in the manufacture of vaccines.

About CureVac
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in the development, optimization and manufacture of this versatile biological molecule for medical purposes. The principle of CureVac’s exclusive technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly develop novel infectious disease prophylactic vaccine products based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates and engineered mRNA vaccine technologies. Based on its proprietary technology, CureVac has built an extensive clinical pipeline in the areas of prophylactic vaccines, cancer therapies, antibody therapies and treatment of rare diseases. CureVac went public on Nasdaq New York in August 2020. It is headquartered in Tübingen, Germany, and employs over 900 people at its locations in Tübingen, Frankfurt and Boston, USA. Further information can be found at

About GSK
GSK is a science-led global healthcare company with one purpose: to help people do more, feel better and live longer. For more information, please visit

CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President of Corporate Communications and Investor Relations
CureVac, Tubingen, Germany
Such. : +49 7071 9883-1298
M: +49 160 90 496949

CureVac Media Contact
Bettina Jödicke-Braas, Communications Manager
CureVac, Tubingen, Germany
Such. : +49 7071 9883-1087

GSK inquiries
Pia Clary, Director of Corporate Communications
GSK Germany
M: +49 152 5323 9052

CureVac Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, beliefs, plans, the objectives, assumptions or projections of CureVac NV and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH, CureVac Inc., CureVac Swiss AG and CureVac Corporate Services GmbH (the “Company”) regarding future events or future results, as opposed to statements that reflect historical facts. Examples include a discussion of the potential effectiveness of the company’s vaccine and treatment candidates and the company’s strategies, funding plans, growth opportunities and market growth. In some cases, you can identify these forward-looking statements by terminology such as “anticipate”, “intend”, “believe”, “estimate”, “plan”, “seek”, “project” or “expect”, “may”, “will”, “would”, “could”, “potential”, “intend” or “should”, the negative of these terms or similar expressions. Forward-looking statements are based on the beliefs management’s current assumptions and assumptions and information currently available to the company. However, these forward-looking statements are not guarantees of the company’s performance and you should not place undue reliance on these statements. Forward-looking statements are subject to numerous risks, uncertainties and other variable circumstances, including adverse global economic conditions and continued instability and volatility in global financial markets, the ability to obtain financing, the ability to ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, dependence on third parties and collaborative partners, the ability to commercialize products , the ability to manufacture products, possible changes in current and proposed legislation, regulations and government policies, increasing competitive pressures and consolidation in the business industry, the effects of the COVID- 19 on the company’s business and operating results, its ability to manage growth, dependence on key personnel, dependence on intellectual property protection, ability to ensure patient safety; and fluctuations in operating results due to the effect of currency exchange rates or o other factors. These risks and uncertainties may cause statements to be inaccurate, and readers are cautioned not to place undue reliance on such statements. Many of these risks are beyond the Company’s control and could cause its actual results to differ materially from those expected to occur. The forward-looking statements included in this press release speak only as of the date hereof. The company does not undertake, and specifically disclaims, any obligation to update these statements or to publicly announce the results of any revisions to these statements to reflect future events or developments, except as required by law.

For more information, please see the company’s reports and documents filed with the United States Securities and Exchange Commission (SEC). You can obtain these documents by visiting EDGAR on the SEC’s website at


See the source version on

James R. Rhodes